|
| Tuesday, January 10, 2023 |
|
|
China Biotech Services subsidiary AMDL nominated as Top Clinical Laboratory Services Company in APAC 2022 and receives CAP Accreditation Certificate |
| China Biotech Services Holdings Limited (the "Group"; stock code: 8037. HK) has announced that its subsidiary, Asia Molecular Diagnostics Laboratory (AMDL), has been nominated as the Top Clinical Laboratory Services Company in APAC 2022 and has received the College of American Pathologists (CAP) Accreditation Certificate for providing next-generation sequencing (NGS) Oncology clinical testing services. more info >> |
|
| Wednesday, April 20, 2022 |
|
|
Actual net profit exceeds FY2020's level, China Biotech Services' (08037) new growth drivers expected to erupt consecutively |
As the pandemic continued to affect the market, China Biotech Services (08037), which owns one of the largest nucleic acid testing laboratories in Hong Kong, recently announced its 2021 annual report.
more info >> |
|
| Tuesday, August 10, 2021 |
|
|
AMDL, a Subsidiary of China Biotech Services, is Exclusively Licensed to Distribute FDA Approved Lung & Colon Cancer Companion Diagnostic Assay in Several Asian Regions Including China |
| China Biotech Services Holdings Limited ("CH BIOTECH SER " or "Company", stock code: 8037.HK) is pleased to announce that Asia Molecular Diagnostic Laboratory ("AMDL"), a subsidiary of the Company, has been exclusively licensed by its shareholder Pillar Biosciences more info >> |
|
| Monday, June 28, 2021 |
|
|
China Biotech (8037.HK): Anticipating promising results from cell therapy and from precision diagnostics |
| 2021-6-23 / Gelonghui - The Company's self-developed cell therapy product was approved by NMPA to enter into phase I clinical trial as a class I new drug more info >> |
|
| Thursday, June 24, 2021 |
|
|
中國生物科技服務(8037.HK)：細胞治療和精准檢測業務雙輪驅動 股東增持彰顯發展信心 |
| （2021-6-23-格隆匯）一、公司自主研發的細胞治療品種作為一類新藥獲批進入臨床一期 more info >> |
|
| Friday, January 29, 2021 |
|
|
上海隆耀首席科学家杨选明教授发表使用OX40优化CAR-T细胞功能相关学术研究 |
| 中国生物科技服务控股有限公司（「中国生物科技服务」或「公司」，股份代号：8037.HK）非全资附属公司上海隆耀生物科技有限公司（「上海隆耀」）首席科学家杨选明教授在美国东部时间2021年1月27日于《科学转化医学期刊》(Science Translational Medicine) 发表关于CD20-CART-OX40研究成果文章。 more info >> |
|
|
上海隆耀首席科學家楊選明教授發表使用OX40優化CAR-T細胞功能相關學術研究 |
| 中國生物科技服務控股有限公司（「中國生物科技服務」或「公司」，股份代號：8037.HK）非全資附屬公司上海隆耀生物科技有限公司（「上海隆耀」）首席科學家楊選明教授在美國東部時間2021年1月27日於《科學轉化醫學期刊》(Science Translational Medicine) 發表關於CD20-CART-OX40研究成果文章。 more info >> |
|
|
Shanghai Longyao Chief Scientist Professor Xuanming Yang published a research article on optimizing CAR-T cells function with independently expressed full-length OX40 |
| China Biotech Services Holdings Limited ("CH BIOTECH SER" or "Company", stock code: 8037.HK) non-wholly-owned subsidiary Shanghai Longyao Biotechnology Co., Ltd. ( "Shanghai Longyao"), the Chief Scientist Professor Xuanming Yang published a CD20-CART-OX40 related research article on January 27, 2021, EST, on Science Translational Medicine. more info >> |
|
| Thursday, January 28, 2021 |
|
|
中国生物科技服务LY007细胞注射液获临床试验批准通知书 |
| 中国生物科技服务控股有限公司（「中国生物科技服务」或「公司」，股份代号：8037.HK）非全资附属公司上海隆耀生物科技有限公司（「上海隆耀」）于2021年1月21日，收到国家药品监督管理局批准名称为LY007的细胞注射液的临床试验之批准通知书，注册分类为I类新药。 more info >> |
|
|
中國生物科技服務LY007細胞注射液獲臨床試驗批准通知書 |
| 中國生物科技服務控股有限公司（「中國生物科技服務」或「公司」，股份代號：8037.HK）非全資附屬公司上海隆耀生物科技有限公司（「上海隆耀」）於2021年1月21日，收到國家藥品監督管理局批准名稱為LY007的細胞注射液的臨床試驗之批准通知書，註冊分類為I類新藥。 more info >> |
|
|
|
|
